These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 38839545)
1. B7-H3: a robust target for immunotherapy in prostate cancer. Pulido R; López JI; Nunes-Xavier CE Trends Cancer; 2024 Jul; 10(7):584-587. PubMed ID: 38839545 [TBL] [Abstract][Full Text] [Related]
2. Potential Therapeutic Targets of B7 Family in Colorectal Cancer. Wang C; Feng H; Cheng X; Liu K; Cai D; Zhao R Front Immunol; 2020; 11():681. PubMed ID: 32477326 [TBL] [Abstract][Full Text] [Related]
3. T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Barach YS; Lee JS; Zang X Trends Mol Med; 2011 Jan; 17(1):47-55. PubMed ID: 20971039 [TBL] [Abstract][Full Text] [Related]
4. B7 homolog 3 in pancreatic cancer. Perovic D; Dusanovic Pjevic M; Perovic V; Grk M; Rasic M; Milickovic M; Mijovic T; Rasic P World J Gastroenterol; 2024 Aug; 30(31):3654-3667. PubMed ID: 39193002 [TBL] [Abstract][Full Text] [Related]
5. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer. Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924 [TBL] [Abstract][Full Text] [Related]
6. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Yang S; Wei W; Zhao Q Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947 [TBL] [Abstract][Full Text] [Related]
7. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells. Zhang Y; He L; Sadagopan A; Ma T; Dotti G; Wang Y; Zheng H; Gao X; Wang D; DeLeo AB; Fan S; Sun R; Yu L; Zhang L; Wang G; Ferrone S; Wang X Mol Cancer Ther; 2021 Mar; 20(3):577-588. PubMed ID: 33653946 [TBL] [Abstract][Full Text] [Related]
8. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400 [TBL] [Abstract][Full Text] [Related]
9. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. Cai D; Li J; Liu D; Hong S; Qiao Q; Sun Q; Li P; Lyu N; Sun T; Xie S; Guo L; Ni L; Jin L; Dong C Cell Mol Immunol; 2020 Mar; 17(3):227-236. PubMed ID: 31611650 [TBL] [Abstract][Full Text] [Related]
10. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population? Liu Y; Vlatkovic L; Sæter T; Servoll E; Waaler G; Nesland JM; Giercksky KE; Axcrona K Int J Urol; 2012 Aug; 19(8):749-56. PubMed ID: 22487487 [TBL] [Abstract][Full Text] [Related]
11. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer. Amori G; Sugawara E; Shigematsu Y; Akiya M; Kunieda J; Yuasa T; Yamamoto S; Yonese J; Takeuchi K; Inamura K Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):767-774. PubMed ID: 33558663 [TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Picarda E; Ohaegbulam KC; Zang X Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063 [TBL] [Abstract][Full Text] [Related]
13. VISTA: A promising target for overcoming immune evasion in gynecologic cancers. Liu S; Ji F; Ding Y; Ding B; Feng S; Brennick C; Lin H; Zhang T; Shen Y Int Immunopharmacol; 2024 Sep; 138():112655. PubMed ID: 38986302 [TBL] [Abstract][Full Text] [Related]
14. High B7-H3 expression is linked to increased risk of prostate cancer progression. Bonk S; Tasdelen P; Kluth M; Hube-Magg C; Makrypidi-Fraune G; Möller K; Höflmayer D; Dwertmann Rico S; Büscheck F; Minner S; Heinzer H; Graefen M; Hinsch A; Luebke AM; Dum D; Uhlig R; Schlomm T; Sauter G; Simon R; Weidemann SA Pathol Int; 2020 Oct; 70(10):733-742. PubMed ID: 32776718 [TBL] [Abstract][Full Text] [Related]
15. Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. Kreymborg K; Haak S; Murali R; Wei J; Waitz R; Gasteiger G; Savage PA; van den Brink MR; Allison JP Cancer Immunol Res; 2015 Aug; 3(8):849-54. PubMed ID: 26122284 [TBL] [Abstract][Full Text] [Related]
16. B7-H3 at the crossroads between tumor plasticity and colorectal cancer progression: a potential target for therapeutic intervention. Varghese E; Samuel SM; Brockmueller A; Shakibaei M; Kubatka P; Büsselberg D Cancer Metastasis Rev; 2024 Mar; 43(1):115-133. PubMed ID: 37768439 [TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer. Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445 [TBL] [Abstract][Full Text] [Related]
18. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma. Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ Front Immunol; 2021; 12():757047. PubMed ID: 34675936 [TBL] [Abstract][Full Text] [Related]
19. The immune regulatory function of B7-H3 in malignancy: spotlight on the IFN-STAT1 axis and regulation of tumor-associated macrophages. Park R; Yu J; Shahzad M; Lee S; Ji JD Immunol Res; 2024 Aug; 72(4):526-537. PubMed ID: 38265550 [TBL] [Abstract][Full Text] [Related]
20. B7-H3 Promotes Prostate Cancer Progression in Mice by Antagonizing Myeloid-Derived Suppressor Cell Apoptosis. Zhou Y; Zhang G; Zhang W; Wei X; Hou J; Huang Y Technol Cancer Res Treat; 2020; 19():1533033820971649. PubMed ID: 33280506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]